Showing results (31-40 of 439) with videos related to
Sort By:
Pageof 44
Current Oncology Reports|March 8, 2018
Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid LeukemiaMassimo Breccia, Robin FoàExpert Opinion on Biological Therapy|December 15, 2010
Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacyMassimo Breccia, Francesco Lo-CocoExpert Opinion on Pharmacotherapy|April 4, 2012
Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent diseaseMassimo Breccia, Francesco Lo-CocoThrombosis Research|May 28, 2014
Thrombo-hemorrhagic deaths in acute promyelocytic leukemiaMassimo Breccia, Francesco Lo CocoExpert Review of Hematology|December 17, 2016
How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changesFulvio Massaro, Matteo Molica, Massimo BrecciaBritish Journal of Haematology|November 27, 2024
Chronic eosinophilic leukaemia-Not otherwise specified: Clinical features, genomic insight and therapeutic strategiesAlessandro Costa, Emilia Scalzulli, Massimo BrecciaMediterranean Journal of Hematology and Infectious Diseases|September 21, 2020
Prognostic Significance of Transcript-Type BCR - ABL1 in Chronic Myeloid LeukemiaMatteo Molica, Elisabetta Abruzzese, Massimo BrecciaCurrent Cancer Drug Targets|October 4, 2017
Ponatinib: A Review of Efficacy and SafetyFulvio Massaro, Matteo Molica, Massimo BrecciaBiodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 18, 2013
Second-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukaemia (CML)Elisabetta Abruzzese, Massimo Breccia, Roberto LatagliataExpert Opinion on Pharmacotherapy|December 1, 2016
Second line small molecule therapy options for treating chronic myeloid leukemiaMatteo Molica, Fulvio Massaro, Massimo BrecciaPageof 44